The FDA has issued warning letters to 30 telehealth firms for making false or misleading claims about compounded versions of popular weight-loss and diabetes drugs like semaglutide — reminding companies they must follow strict safety rules to protect patients.
🔗
https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s
#FDAAlert #HealthNews 🌿
